A prospective pilot study in Italy reports that gallium-68 labeled PSMA-11 PET/MR can illuminate disease in prostate cancer and help predict relapse timing. The report centers on imaging performance, proposing the approach as a way to identify high-risk recurrence earlier than conventional post-operative monitoring. The study is described as multicentre, with researchers testing whether the imaging signal correlates with later relapse outcomes before surgery. If validated, it could improve stratification for follow-up intensity and adjuvant decisions. PSMA-targeted PET imaging is already reshaping detection for prostate cancer; the added value here is integrating a broader imaging workflow to guide recurrence risk. For the clinic and developers, earlier detection is directly tied to better trial enrichment for interventions in recurrent disease settings.